NASDAQ: VAXXVaxxinity Inc Stock
$0.12-0.01 (-7.69%)
Updated Apr 25, 2024
VAXX Price
$0.12
Fair Value Price
-$0.08
Market Cap
$15.34M
52 Week Low
$0.12
52 Week High
$3.10
P/E
-0.27x
P/B
1.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$56.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.31
Operating Cash Flow
-$57M
Beta
0.95
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VAXX Overview
Vaxxinity Incorporated develops products in the fields of neurology and coronaviruses in the U.S. Its pipeline includes UB-311, in Phase 2 clinical trials to treat Alzheimer's disease, UB-312 to treat Parkinson's disease, and UB-612, in Phase 3 clinical trials to neutralize the SARS-CoV-2 virus. The company was founded in 2014 and is headquartered in Dallas, TX.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VAXX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VAXX ($0.12) is overvalued by 251.08% relative to our estimate of its Fair Value price of -$0.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VAXX ($0.12) is not significantly undervalued (251.08%) relative to our estimate of its Fair Value price of -$0.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VAXX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VAXX due diligence checks available for Premium users.
Be the first to know about important VAXX news, forecast changes, insider trades & much more!
VAXX News
Valuation
VAXX fair value
Fair Value of VAXX stock based on Discounted Cash Flow (DCF)
Price
$0.12
Fair Value
-$0.08
Undervalued by
249.83%
VAXX ($0.12) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VAXX ($0.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VAXX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VAXX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.27x
Industry
15.41x
Market
40.97x
VAXX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.14x
Industry
5.8x
VAXX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VAXX's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.4M
Profit Margin
0%
VAXX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$44.3M
Liabilities
$30.9M
Debt to equity
2.31
VAXX's short-term assets ($33.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VAXX's short-term assets ($33.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VAXX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.8M
Investing
-$407.0k
Financing
-$313.0k
VAXX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VAXX vs Biotech Stocks
Vaxxinity Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.